Drugs Xagena
Genentech and FDA ( Food and Drug Administration ) informed HealthCare Providers of important new safety information regarding Avastain ( Bevacizumab ). Tracheoesophageal fistula has been seen in ...
The FDA ( Food and Drug Administration ) has approved Ixempra ( Ixabepilone ), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded ...
A new pilot study by Researchers at Memorial Sloan-Kettering Cancer Center ( MSKCC ) found that breast cancer patients can be treated safely with a dose-dense regimen of standard chemotherapy agents a ...
The safety and maximum tolerated dose ( MTD ) of sunitinib malate( Sutent ) in combination with Bevacizumab ( Avastin ) has been assessed in patients with metastatic renal cell carcinoma ( mRCC ) in a ...
The FDA ( Food and Drug Administration ) has announced that the Agency is recommending removing the breast cancer indication from the label for Avastin ( Bevacizumab ) because the drug has not been sh ...
The FDA ( Food and Drug Administration ) has assigned Priority Review to the regulatory submission for Ramucirumab as a single-agent treatment for advanced gastric cancer following disease progression ...
The European Commission ( EU ) has approved the use of Avastin ( Bevacizumab ) in combination with Paclitaxel, Topotecan, or Pegylated liposomal doxorubicin chemotherapy as a treatment for women with ...
The European Medicines Agency's ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion for Abraxane ( Paclitaxel formulated as albumin-bound nanoparticles, or N ...
The ASCO Task Force has applied the Framework to four clinical scenarios in which multiple trials have compared new treatment options with current standards of care: first-line treatment for metastati ...
Opdivo, a PD-1 checkpoint inhibitor approved in Europe, for both first-line and previously-treated advanced melanoma patients The European Commission has approved Opdivo ( Nivolumab ), a PD-1 immu ...
The FDA ( Food and Drug Administration ) has approved Iressa ( Gefitinib ) for the first-line treatment of patients with metastatic non-small cell lung cancer ( NSCLC ) whose tumors harbor specific ty ...
The Chemotherapy Clinical Reference Group ( CRG ) has reviewed drugs and drug indications for inclusion on the National cancer drugs fund list. The decision summaries record how each drug/drug indica ...
The Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab), an anti-PD-1 ( programmed death receptor-1 ) therapy, for the first-line treatment of patients with metastatic non-smal ...
The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with Carboplatin and either Paclitaxel or nab-Paclitaxel, for the first-line ...
The FDA ( US Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) in combination with Avastin ( Bevacizumab ), Paclitaxel and Carboplatin ( chemotherapy ), for the initial ( first-li ...
The European Commission has approved Tecentriq ( Atezolizumab ) plus chemotherapy ( Abraxane [ Paclitaxel protein-bound particles for injectable suspension ( albumin-bound ); nab-Paclitaxel ] ) for th ...
The FDA ( US Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) in combination with chemotherapy ( Abraxane [ Paclitaxel protein-bound; nab-Paclitaxel ] and Carboplatin ) for the i ...
Opdivo ( Nivolumab ) was approved by the U.S. Food and Drug Administration ( FDA ) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma ...
The FDA ( Food and Drug Administration ) has approved Enhertu ( fam-Trastuzumab Deruxtecan-nxki; fam-Trastuzumab Deruxtecan ) for adult patients with locally advanced or metastatic HER2-positive gastr ...
The U.S. Food and Drug Administration ( FDA ) has approved the combination of Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, plus Lenvima ( Lenvatinib ), the orally available multiple receptor tyro ...
The Food and Drug Administration ( FDA ) has approved Enhertu ( fam-Trastuzumab Deruxtecan-nxki; Trastuzumab Deruxtecan ) for adult patients with unresectable or metastatic HER2-low ( IHC 1+ or IHC 2+ ...
